When and where: A study on gastric cancer recurrence after neoadjuvant/perioperative chemotherapy

doi:10.3748/wjg.117778

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 30

This Article

(25)

(20)

(0)

(334)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Randomized Controlled Trial

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Aug 14, 2026; 32(30): 117778
Published online Aug 14, 2026. doi: 10.3748/wjg.117778

Table 1 Baseline patient characteristics (n = 91), n (%)

	*A: 4 DOC + surgery (n =* 46)**	*B: 2 DOC + surgery + 2 DOC (n =* 45)**	Overall
Median age, years (range)	63 (39-74)	66 (33-75)	64 (33-75)
Gender
Male	32 (69.6)	32 (71.1)	64 (70.3)
Female	14 (30.4)	13 (28.9)	27 (29.7)
ECOG performance status
0	42 (91.3)	43 (95.6)	85 (93.4)
1	4 (8.7)	2 (4.4)	6 (6.6)
cTN
T2N+	2 (4.3)	1 (2.2)	3 (3.3)
T3N0	8 (17.4)	5 (11.1)	13 (14.2)
T3N+	18 (39.1)	16 (35.6)	34 (37.4)
T4aN0	4 (8.7)	3 (6.7)	7 (7.7)
T4aN+	13 (28.3)	18 (40.0)	31 (34.1)
T4bN+	1 (2.2)	2 (4.4)	3 (3.3)
cT
T2	2 (4.3)	1 (2.2)	3 (3.3)
T3	26 (56.5)	21 (46.7)	47 (51.6)
T4a	17 (37.0)	21 (46.7)	38 (41.8)
T4b	1 (2.2)	2 (4.4)	3 (3.3)
cN
N0	12 (26.1)	8 (17.8)	20 (22.0)
N1	14 (30.4)	16 (35.6)	30 (33.0)
N2	4 (8.7)	7 (15.6)	11 (12.0)
N3	3 (6.5)	3 (6.7)	6 (6.6)
N+	13 (28.3)	11 (24.3)	24 (26.4)
Response to treatment (Becker + lymph nodes)
Poor response	27 (62.8)	32 (78.1)	59 (70.2)
Good response	16 (37.2)	9 (21.9)	25 (29.8)
Unknown	3	4	7
Lauren histotype
Diffuse	22 (50.0)	13 (29.5)	35 (39.8)
Intestinal	18 (40.9)	23 (52.3)	41 (46.6)
Other	4 (9.1)	8 (18.2)	12 (13.6)
Unknown	2	1	3

ECOG: Eastern Cooperative Oncology Group; DOC: Docetaxel, oxaliplatin, capecitabine.

Full Size Table

Citation: Monti M, Ceredi B, Foca F, Morgagni P, Framarini M, Vertogen B, Marrelli D, Roviello F, Fumagalli Romario U, Bozzarelli S, Donini A, Graziosi L, Filippini F, Bencivenga M, Milandri C, Mura G, Baiocchi GL, Rausei S, Molinari C, Passardi A. When and where: A study on gastric cancer recurrence after neoadjuvant/perioperative chemotherapy. World J Gastroenterol 2026; 32(30): 117778
URL: https://www.wjgnet.com/1007-9327/full/v32/i30/117778.htm
DOI: https://dx.doi.org/10.3748/wjg.117778

Monti M, Ceredi B, Foca F, Morgagni P, Framarini M, Vertogen B, Marrelli D, Roviello F, Fumagalli Romario U, Bozzarelli S, Donini A, Graziosi L, Filippini F, Bencivenga M, Milandri C, Mura G, Baiocchi GL, Rausei S, Molinari C, Passardi A. When and where: A study on gastric cancer recurrence after neoadjuvant/perioperative chemotherapy. World J Gastroenterol 2026; 32(30): 117778 [DOI: 10.3748/wjg.117778]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.